peripheral t-cell lymphoma treatment regimen still safe and efficacious at 5-year follow-up
Published 3 years ago • 603 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
2:54
brentuximab vedotin continues to provide improvement for peripheral t-cell lymphoma patients
-
6:13
understanding peripheral t-cell lymphoma with dr. pamela blair allen
-
2:03
5-year follow-up of echelon-2: a chp vs chop for cd30 ptcl
-
2:27
long-term efficacy and safety of brentuximab vedotin in hodgkin lymphoma patients
-
4:35
understanding peripheral t-cell lymphoma
-
27:06
peripheral t-cell lymphoma: what is new on the horizon?
-
1:15
insights into the treatment of peripheral t-cell lymphomas and the role of autologous transplant
-
7:40
support shown for brentuximab vedotin for treatment of systemic anaplastic large cell lymphoma
-
2:27
the current standard of care for patients with ptcl
-
15:03
treatment selection for peripheral t-cell lymphomas
-
55:09
peripheral t-cell lymphomas: confusion in a perplexing disease
-
1:16
highlights in ptcl at ash 2022
-
1:01:48
update on t cell lymphoma | lrf webinars
-
5:20
novel treatment strategies for peripheral t-cell lymphomas
-
2:26
belinostat toxicity and safety in peripheral t-cell lymphomas - video abstract id 149241
-
19:42
t-cell lymphoma
-
0:54
challenges impacting treatment of cutaneous and peripheral t-cell lymphomas
-
2:39
peripheral t-cell lymphoma classifications and cd30 testing
-
0:51
the need for novel agents for the treatment of ptcl